Stockreport

Astria Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update [Yahoo! Finance]

Astria Therapeutics, Inc.  (ATXS) 
PDF -- Initial Efficacy and Safety Data from Navenibart ALPHA-SOLAR Long-Term Extension Trial Expected Mid-2025 -- -- Phase 1a Trial of STAR-0310, a Potential Best-in-Cla [Read more]